Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M. - ND
- Conditions
- metastatised breast cancer, first line treatmentLevel: PTClassification code 10057654
- Registration Number
- EUCTR2007-003156-11-IT
- Lead Sponsor
- GOIM GRUPPO ONCOLOGICO MERIDIONALE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
histologically confirmed metastatic breast cancer, tumor overexpressing HER2/neu (+++)or with HER2/neu
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
previous chemiotherapy for metastatic disease, concomitant serious diseases (cardiovascular, renal etc.), preesistent neuropathy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method